skip to Main Content
Nataša Skoko

Nataša Skoko

Head of Biotech Development Unit at ICGEB, Italy

Dr. Skoko graduated in Molecular Biology and obtained MSc degree in Molecular Biology and Biochemistry working in the Molecular Biotechnology Group at the IMGGE in Belgrade. From 2003 to 2006, she was a research fellow in the Molecular Pathology Laboratory at the ICGEB in Trieste. She obtained a Ph.D degree in 2006 when she started to work as a research scientist in the Biotechnology Development Unit (BDU) at ICGEB on the development of technologies for the production of biosimilars. Since 2018, Dr. Skoko is a Group Leader of BDU and her current interest is focused on development of biosimilar to Trastuzumab, Certolizumab pegol and Liraglutide.

14:30 - 15:30

Parallel sessions

Academia session: Biotechnology - How is it shaping our future?

Moderator and chair of the session: Dr. Jelena Begović, Director of Institute of Molecular Genetics and Genetic Engineering (IMGGE) and Full Research Professor

  • Dr. Charles Ruranga, Director of the African Centre of Excellence in Data Science, Rwanda 
  • Dr. Claudia Vickers, Chief Scientific Officer at Eden Brew, Australia
  • Kiren Naidoo, CEO of Zdravlje A.D. and Founder of Frontier Pharma, UK
  • Martin Mössler, Managing Director of Science Park Graz, Austria
  • Dr. Nataša Skoko, Head of Biotechnology Development Unit at International Centre for Genetic Engineering and Biotechnology, Italy

Business session: Accelerating innovation

Moderator and chair of the session: Prof. Robert C. Wolcott, Co-Founder and Chairman of The World Innovation Network (TWIN) and Adjunct Professor of Innovation at Booth School of Business at University of Chicago & Kellogg School of Management at Northwestern University

  • Dan Vahdat, CEO of Huma, UK
  • Gloria Seibert, Founder & CEO at Temedica, Germany 
  • Dr. Milan Obradović, Senior Global Scientific Director Integrated Healthcare Solutions, Global Medical Affairs at Roche, Switzerland 
  • Dr. Ulrich A.K. Betz, Vice President Innovation in Merck, Germany
  • William Moss, CEO of Seven Bridges Genomics, USA

Back To Top